Congratulations to our CEO, President and Founder, Dr. Emil Kakkis,  on being honored as BIO’s 2019 Henri A. Termeer Biotechnology Visionary Award recipient for his transformative work in rare diseases. Read more.

January 15, 2020
GeneTx and Ultragenyx Announce Investigational New Drug (IND) Application Active for GTX-102 in Patients with Angelman Syndrome

January 13, 2020
Ultragenyx Reports Preliminary 2019 Revenue and Provides 2020 Crysvita Revenue Guidance

January 13, 2020
Ultragenyx and Kyowa Kirin Announce Submission of Supplemental Biologics License Application to U.S. FDA for Crysvita® (burosumab) for Tumor-Induced Osteomalacia (TIO)